Products for Research Use Only

Venetoclax

CAT: 0804-HY-15531-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15531-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy[1][2][3].
CAS Number
1257044-40-8
Product Name Alternative
ABT-199; GDC-0199; RG7601
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H361, H373
Target
Autophagy; Bcl-2 Family
Type
Reference compound
Related Pathways
Apoptosis; Autophagy
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ABT-199.html
Purity
99.96
Solubility
DMSO : 77.5 mg/mL (ultrasonic) |Ethanol : < 1 mg/mL
Smiles
O=C(NS(=O)(C1=CC=C(NCC2CCOCC2)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4CCN(CC5=C(C6=CC=C(Cl)C=C6)CC(C)(C)CC5)CC4)C=C3OC7=CN=C(NC=C8)C8=C7
Molecular Formula
C45H50ClN7O7S
Molecular Weight
868.44
Precautions
H302, H315, H319, H361, H373
References & Citations
[1]Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19 (2) :202-8.|[2]Peirs S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014 Dec 11;124 (25) :3738-47.|[3]Bi C, et al. Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. Haematologica. 2017 Apr;102 (4) :755-764.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
Bcl-2; Bcl-W; Bcl-xL